EpistemisAtlas of Pharmacological Selection and Systemic Toxicity Profile
A rigorous ophthalmic formulary requires mapping therapeutic profiles and cross-systemic risks. The following matrix summarizes the molecular targets, biological risks, and prescription adjustments needed at the professional point of care.
File
| Drug | Critical Molecular Target | Ocular Mechanism of IOP/Effect | Risk of Major Systemic Toxicity | Mandatory Prescription Adjustment |
|---|---|---|---|---|
| Latanoprost | Selective FP (Gq) Receptor Agonist | Increased uveoscleral drainage | Very low; local iris hyperpigmentation | Does not require adjustments; single night dose |
| Timolol | Competitive β1/β2 adrenergic blocker | Reduction of aqueous humor synthesis | Lethal bronchospasm / Severe bradycardia | Contraindicated in Asthma, COPD and AV Block |
| Brimonidine | Selective α2 adrenergic agonist (Gi) | Dual mechanism: reduces synthesis and increases flow | Respiratory depression in infants / Coma | Absolutely contraindicated in children < 2-6 years old |
| Dorzolamide | Selective inhibitor of Carbonic Anhydrase II | Decreased active bicarbonate cotransport | Mild metabolic acidosis / Pharyngeal dysgeusia | Avoid in moderate-severe renal failure |
| Netarsudil | ROCK-1 and ROCK-2 kinase inhibitor | Relaxation of the conventional trabecular cytoskeleton | Low; follicular conjunctivitis / Vortex keratopathy | Does not require organic adjustments; night dose |
| Pilocarpine | Direct muscarinic cholinergic agonist (M3) | Pupillary contraction and trabecular meshwork traction | Diaphoresis / Myopic accommodation spasm | Avoid in high myopes (Retinal Detachment) |
| Atropine | Competitive muscarinic antagonist (M3) | Passive mydriasis and total cycloplegia due to paralysis | Central psychotic delirium / Hyperthermia / Anhidrosis | Obligate punctal occlusion in children and the elderly |
| Phenylephrine | Selective α1 adrenergic agonist | Active mydriasis without cycloplegia due to vasoconstriction | Acute hypertensive crisis / Myocardial infarction | Avoid 10% concentration in severe heart disease |
| Prednisolone | Glucocorticoid receptor (GR) agonist | Inhibition of PLA2 (via lipocortin-1) and NF-κB | Steroidal glaucoma / Subcapsular cataracts | Monitor IOP biweekly; gradually withdraw |
| Nepafenac | Reversible inhibitor of COX-1 and COX-2 enzymes | Prevention of postoperative miosis and macular edema | Corneal dural keratolysis (corneal melting) | Discontinue if there are signs of corneal epithelial defect |
| Olopatadine | H1 receptor antagonist and mast cell inhibitor | Immediate blockage of pruritus and cellular stabilization | Minimal; mild conjunctival dryness | Remove contact lenses before instillation |
| Cyclosporin A | Inhibitor of calcineurin / NFAT in T lymphocytes | Restoration of goblet cells and tears | Intense transient initial conjunctival burning | Requires 3 to 6 months to evaluate response |
| Moxifloxacin | DNA-Gyrase and Topoisomerase IV inhibitor | Broad-spectrum stromal bactericidal effect | Minimal; Local erythema and reflex tearing | Reserve for severe keratitis or conjunctivitis |
| Ganciclovir | Nucleoside analogue (viral chain terminator) | Selective inhibition of viral DNA polymerase | Mild epithelial punctate keratopathy | Avoid use of corticosteroids in active herpetic keratitis |
| Natamycin | Polyene membrane macrolide due to ergosterol | Alters fungal permeability of filamentous cells | Severe epitheliotoxicity / Acute corneal pain | Perform prior corneal scraping in deep infiltrates |
| Aflibercept | VEGF-A, VEGF-B and PlGF trap fusion protein | Inhibition of choroidal retinal neovascular receptor | Bacterial endophthalmitis / Retinal tear | Strict injection under sterile technique in the operating room |
| Fluorescein | Dural fluorophore of intercellular junctions | Selective staining of defects and angiography | Idiopathic anaphylactic shock (IV injection) | Have a stop cart with adrenaline for angiography |
| Hyaluronic Acid | Non-Newtonian viscoelastic polymer | Water retention and prolongation of corneal TBUT | Minimal; transient post-blink blurred vision | Use preservative-free formulations in severe dry eye |
The Three Commandments of the Ophthalmological Prescriber
To ensure safe ophthalmic clinical practice, the following guidelines should be applied:
- Is there a cardiorespiratory risk? Never prescribe timolol or other topical beta blockers without ruling out a history of asthma or symptomatic bradycardia. If in doubt, select betaxolol or prostaglandin analogues.
- Has active herpetic keratitis been ruled out? In case of any corneal inflammation or painful "red eye" of unknown cause, perform fluorescein staining before prescribing topical corticosteroids to avoid giant geographic necrosis due to virus replication.
- Is the treatment long-term? If you prescribe artificial tears or eye drops for chronic pathologies (glaucoma, dry eye) that require more than 4 instillations per day, systematically require preservative-free formulations to avoid epithelial accumulation of benzalkonium chloride, a powerful inducer of iatrogenic keratopathy.
"The eye is an optical window to the organism, and its barriers are physical testimony to the precision of pharmacology." — Ocular Therapeutic Axiom.
Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.
- System
- Ophthalmology
- Cluster
- Integrated Clinical Selection and Reference Guide